Inhibition of pyroptosis abrogates MDS HSPC death and augments CFC. (A-B) Fold change in the mean percentage of (A) pyroptotic or (B) apoptotic cells in each respective lineage in LR-MDS BM-MNCs (n = 6) incubated with autologous BM plasma and 0.5 µg CD33-IgG₁ chimera for 24 hours. Values are normalized to autologous BM plasma-incubated MDS BM-MNCs. (C) qPCR analysis of BM-MNCs isolated from LR-MDS patients (n = 5) treated for 24 hours with CD33-IgG₁. (D-E) CFC was assessed in BM-MNCs from LR-MDS patient specimens (n = 3) treated with increasing concentrations of CD33-IgG₁ (E) or the inflammasome inhibitor MCC950 (E). Error bars represent SE.